Search

Your search keyword '"Lobbedez T"' showing total 463 results
Start Over Author "Lobbedez T"
463 results on '"Lobbedez T"'

2. Healthcare professional education in shared decision making in the context of chronic kidney disease: a scoping review

Author

Meijers B., Wellekens K., Montomoli M., Altabas K., Geter J., McCarthy K., Lobbedez T., Kazancioglu R., Thomas N., and KAZANCIOĞLU, RÜMEYZA

Abstract

Rationale & objective: Shared decision making (SDM) is a collaborative effort between healthcare professionals, individuals with CKD whereby clinical evidence, expected outcomes and potential side-effects are balanced with individual values and beliefs to provide the best mutually decided treatment option. Meaningful SDM is supported by effective training and education. We aimed to identify the available evidence on SDM training and education of healthcare professionals caring for people with chronic kidney disease. We aimed to identify existing training programs and to explore what means are used to evaluate the quality and effectiveness of these educational efforts. Methodology: We performed a scoping review to study the effectiveness of training or education about shared decision making of healthcare professionals treating patients with kidney disease. EMBASE, MEDLINE, CINAHL and APA PsycInfo were searched. Results: After screening of 1190 articles, 24 articles were included for analysis, of which 20 were suitable for quality appraisal. These included 2 systematic reviews, 1 cohort study, 7 qualitative studies, and 10 studies using mixed methods. Study quality was varied with high quality (n = 5), medium quality (n = 12), and low quality (n = 3) studies. The majority of studies (n = 11) explored SDM education for nurses, and physicians (n = 11). Other HCP profiles included social workers (n = 6), dieticians (n = 4), and technicians (n = 2). Topics included education on SDM in withholding of dialysis, modality choice, patient engagement, and end-of-life decisions. Limitations: We observed significant heterogeneity in study design and varied quality of the data. As the literature search is restricted to evidence published between January 2000 and March 2021, relevant literature outside of this time window has not been taken into account. Conclusions: Evidence on training and education of SDM for healthcare professionals taking care of patients with CKD is limited. Curricula are not standardized, and educational and training materials do not belong to the public domain. The extent to which interventions have improved the process of shared-decision making is tested mostly by pre-post testing of healthcare professionals, whereas the impact from the patient perspective for the most part remains untested.

Published
2023

4. Contre-indication temporaire de l’accès à la greffe rénale : existe-t-il des différences entre les femmes et les hommes inscrits sur la liste d’attente ? [Conference abstract]

Author

Adoli, L., Châtelet, V., Daugas, E., Lobbedez, T., Vabret, E., Jais, J.P., Bayer, F., Vigneau, C., Couchoud, C., Bayat, Sahar, École des Hautes Études en Santé Publique [EHESP] (EHESP), Département Méthodes quantitatives en santé publique (METIS), Centre de Recherches sur l'Action Politique en Europe (ARENES), and Université de Rennes (UR)-Institut d'Études Politiques [IEP] - Rennes-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Centre National de la Recherche Scientifique (CNRS)

Subjects
Accès, Contre-indications temporaires (CIT), [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Disparité femme/homme, Greffe rénale
Abstract

International audience; Introduction :En France, peu d’études se sont intéressées aux rôles des contre-indications temporaires (CIT) dans la disparité femme/homme de l’accès à la greffe. Notre objectif est de comparer les CIT entre les hommes et les femmes en distinguant les mises en CIT dès l’inscription et celles après avoir été actif sur la liste.Description/méthodes :Les données des insuffisants rénaux chroniques, âgés de 18 à 85 ans, ayant débuté la dialyse en 2017/2018 en France ont été extraites du registre REIN. Les raisons et durées de mise en CIT des patients inscrits sur la liste ont été comparées entre les femmes et les hommes.Résultats :Au total, 19 478 patients ont été inclus. Au 31/12/2020, 32,67 % étaient inscrits sur la liste d’attente. Parmi les inscrits, la moyenne d’âge est respectivement de 55 ans (±14 ans) et 57 ans (±14 ans) chez les femmes et les hommes. Au total, 21,3 % des femmes et 35,3 % des hommes présentaient au moins une maladie cardiovasculaire. 4611 patients étaient mis en CIT dès l’inscription (73 % des femmes et 72 % des hommes inscrits). Les femmes passent une durée médiane de 155 jours (IIQ : 65–223) en CIT versus 154 jours (IIQ : 70–330) chez les hommes. Le bilan pré-greffe incomplet est la cause principale (79 %) de ces CIT quel que soit le sexe.51 % des femmes et 52 % des hommes inscrits ont été mis en CIT ultérieurement. Les femmes et les hommes restent inactifs en médiane 79 jours par CIT. 8,3 % des CIT des femmes et 14,4 % des CIT des hommes sont de causes cardiovasculaires.Conclusion :Aucune différence n’a été observée sur le recours aux CIT ou sur leur durée entre les femmes et les hommes. Une fois inscrits, les CIT n’expliquent pas les disparités femmes/hommes dans l’accès à la greffe rénale en France.

Published
2022

11. Early infectious risk in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis according to remission-induction therapy.

Author

Gérard, M, de Boysson, H, Morello, R, Martin-Silva, N, Leroux, A-C, Dumont, A, Maigné, G, Boutemy, J, Khoy, K, Mariotte, D, Lobbedez, T, Aouba, A, and Deshayes, S

Subjects
MICROSCOPIC polyangiitis, REMISSION induction, ANTINEUTROPHIL cytoplasmic antibodies, GRANULOMATOSIS with polyangiitis, VASCULITIS
Abstract

Few comparative data exist on early infections secondary to remission-induction therapy (RIT) with rituximab (RTX) versus cyclophosphamide (CYC) in newly diagnosed anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) patients. We compared and analysed the rates and predictors of severe infection in such patients within the first 6 months following RIT. From the Caen University Hospital databases, we included all consecutive adults newly diagnosed with ANCA-positive granulomatosis with polyangiitis or microscopic polyangiitis between January 2006 and December 2019. We compared rates of survival without severe infection and survival without infections of any severity within 6 months of RIT and used a multivariate Cox analysis to identify predictors of infection. We included 145 patients, 27 in the RTX and 118 in the CYC group. Patients in the RTX group more frequently had pneumococcal vaccination (p < 0.01) and creatinine < 150 µmol/L; other characteristics were comparable between the two groups. Overall, 37 severe infections and 65 infections of any severity were recorded. Rates of survival without severe infection were similar in both groups (p = 0.69), but survival without infections of any severity was lower in the RTX group (p = 0.005). In multivariate analysis, risk factors at diagnosis for severe infections included chronic urinary tract disease, dialysis, and absence of trimethoprim–sulfamethoxazole prophylaxis (p < 0.01 each). Within 6 months of RIT, rates of survival without severe infection were similar in newly diagnosed ANCA-positive AAV patients treated with RTX or CYC, but survival rates without infections of any severity appeared to be lower with RTX treatment. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

13. Early infectious risk in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis according to remission-induction therapy

Author

Gérard, M, primary, de Boysson, H, additional, Morello, R, additional, Martin-Silva, N, additional, Leroux, A-C, additional, Dumont, A, additional, Maigné, G, additional, Boutemy, J, additional, Khoy, K, additional, Mariotte, D, additional, Lobbedez, T, additional, Aouba, A, additional, and Deshayes, S, additional

Published
2022
Full Text
View/download PDF

14. Long-Term Outcomes Among Participants in the WEGENT Trial of Remission-Maintenance Therapy for Granulomatosis With Polyangiitis (Wegenerʼs) or Microscopic Polyangiitis

Author

Puéchal, Xavier, Pagnoux, Christian, Perrodeau, Élodie, Hamidou, Mohamed, Boffa, Jean-Jacques, Kyndt, Xavier, Lifermann, François, Papo, Thomas, Merrien, Dominique, Smail, Amar, Delaval, Philippe, Hanrotel-Saliou, Catherine, Imbert, Bernard, Khouatra, Chahéra, Lambert, Marc, Leské, Charles, Ly, Kim H., Pertuiset, Edouard, Roblot, Pascal, Ruivard, Marc, Subra, Jean-François, Viallard, Jean-François, Terrier, Benjamin, Cohen, Pascal, Mouthon, Luc, Le Jeunne, Claire, Ravaud, Philippe, Guillevin, Loïc, Rispal, P., Baidi, N., Chrétien, O., Cevallos, R., Ducroix, J.-P., Darmaillacq, J.-G., Dubas, F., Maghakian, M.-N., Moreau, C., Dubos-Arvis, C., Frognier, R., Gobert, P., Pollini, J., Pingat, D., Janin-Manificat, L., Lafon, B., Kettaneh, A., Moiton, M., Ragnaud, J. M., Boudray, C., Raphanel, B., Renand, J.-P., Roux, M., Bonnaire, G., Guiso, A., André, J. M., Perrichot, R., Louvet, J., Artigues, N., Bienvenu, B., de Ligny, Hurault B., Le Hello, C., Letellier, P., Lobbedez, T., Ollivier, Y., Pujo, M., Ryckelynck, J.-P., Montseny, J.-J., Collet, P., Ayach, B., Dion, J.-J., Mouawad, H., Damade, R., Dupouët, L., Asgaraly, K., Depernet, B., Colin, T., Ioos, V., Rieu, V., Belmatoug, N., Foulon, L., Jebrak, G., du Coedic, L., Bachmeyer, C., Dumoulin, A., Godeau, B., Khellaf, M., Michel, M., Pastural, M., Schaeffer, A., Geffroy, M., Bielefeld, P., Fichet, D., Saraux, J.-L., Vinzio, S., Ehrlacher, P., Azria, A., Mariette, X., Tiab, M., Delansorne, D., Boullanger, N., Closs-Prophette, F., Goldstein, A., Bouscaud, L., Meunier, V., Hachulla, E., Hatron, P.-Y., Launay, D., Hottelart, C., Liozon, E., Longuet, O., Loustaud-Ratti, V., Soria, P., Vidal, E., Geffray, L., Henri, P., Landru, I., Guillemot, J.-M., Le Noach, J., Cordier, J.-F., Cottin, V., Gentil, B., Demolombe-Rague, S., Girard-Madoux, M.-H., Ninet, J., Pinède, L., Meynieux, J.-P., Serratrice, J., Xeridat, B., Bagnères, D., Roudier, J., Denis, B., Boillet, N., Geraads, A., Teyssandier, R., Degraeve, F., Le Quellec, A., Rivière, S., Rogé, C., Fauchay, J.-P., Wahl, D., Agard, C., Généreau, T., Meker, D., Bensakel, S., Vecina, F., Aubier, M., Foulon, G., Lelièvre, P., Lidove, O., Mignon, F., Meyer, O., Piperaud, M., Queffeulou, G., Vrtovsnik, F., Aouba, A., Arène, J.-P., Bérezné, A., Le Guern, V., Amoura, Z., Benveniste, O., Dimitri, D., Huong, Lê Thi D., Bergeron, A., Bourgarit, A., Farge, D., Mahr, A., Martinez, F., Séréni, D., Aslangul, E., Arnal, C., Cadranel, J., Daugas, E., Pelle, G., Rossert, J., Wislez, M., Gayraud, M., Bruet, A., Hillion, Y., Paccalin, M., Léone, J., Pennaforte, J.-L., Barbier, S., Legallicier, B., Dominique, S., Charasse, C., Coëtmeur, D., Duhamel, E., Goulias, J.-P., Bournerias, F., Gautherie, P., Schlienger, J.-L., Vidal, A., Diot, E., Diot, P., Vanhille, P., Bindi, P., and Cervantes, G.

Published
2016
Full Text
View/download PDF

22. Risque infectieux associé au traitement d’induction des vascularites à ANCA : une étude rétrospective monocentrique française incluant 145 patients

Author

Gérard, M., primary, De Boysson, H., additional, Morello, R., additional, Martin Silva, N., additional, Dumont, A., additional, Maigné, G., additional, Boutemy, J., additional, Khoy, K., additional, Mariotte, D., additional, Lobbedez, T., additional, Aouba, A., additional, and Deshayes, S., additional

Published
2021
Full Text
View/download PDF

25. POS0831 EARLY INFECTIOUS RISK IN PATIENTS WITH NEWLY-DIAGNOSED ANTI-NEUTROPHILCYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS ACCORDING TO THE REMISSION-INDUCTIONTHERAPY: A FRENCH MONOCENTRIC RETROSPECTIVE STUDY INCLUDING 145 PATIENTS

Author

Gérard, M., primary, De Boysson, H., additional, Morello, R., additional, Silva, N. M., additional, Leroux, A. C., additional, Dumont, A., additional, Maigné, G., additional, Boutemy, J., additional, Khoy, K., additional, Mariotte, D., additional, Lobbedez, T., additional, Aouba, A., additional, and Deshayes, S., additional

Published
2021
Full Text
View/download PDF

37. 12-3 - La défaveur sociale et les comorbidités expliquent-elles le moindre accès des femmes à la greffe rénale en France ?

Author

Komla Adoli, L., Couchoud, C., Chatelet, V., Lobbedez, T., Bayer, F., Vabret, E., Jais, J-P., Daugas, E., Vigneau, C., and Bayat, S.

Abstract

Plusieurs études menées au niveau international ou dans certaines régions françaises, font état d'un faible accès à la greffe rénale des femmes. Cette étude vise à analyser l'accès à la greffe rénale des femmes en France en prenant en compte la défaveur sociale et les comorbidités.

Published
2024
Full Text
View/download PDF

39. Prevalence of atheromatous and non-atheromatous cardiovascular disease by age in chronic kidney disease

Author

Villain, Cédric, Metzger, Marie, Combe, Christian, Fouque, Denis, Frimat, Luc, Jacquelinet, Christian, Laville, Maurice, Briançon, Serge, Klein, Julie, Schanstra, Joost, Robinson, Bruce, Mansencal, Nicolas, Stengel, Bénédicte, Massy, Ziad, Hannedouche, T, Moulin, B., Klein, A, Bourdenx, J, Keller, A, Delclaux, C, Vendrely, B., Deroure, B, Lacraz, A, Lobbedez, T., Landru, I, Lang, P., Belenfant, X., Thervet, E., Urena, P, Delahousse, M, Vela, C, Essig, M, Sekhri, H, Smati, M, Jamali, M, Hacq, B, Panescu, V, Bellou, M, Kamar, Nassim, Noël, C., Glowacki, F., Maisonneuve, N, Azar, R., Hoffmann, M, Hourmant, M., Testa, A, Besnier, D., Choukroun, Gabriel, Lambrey, G, Burtey, Stéphane, Lebrun, G, Magnant, E, Juillard, L., Chazot, C, Zaoui, P, Kuentz, F, Hôpital Ambroise Paré [AP-HP], Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Néphrologie-Transplantation-Dialyse, CHU Bordeaux [Bordeaux]-Groupe hospitalier Pellegrin, Bioingénierie tissulaire (BIOTIS), Université de Bordeaux (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Maladies chroniques, santé perçue, et processus d'adaptation (APEMAC), Université de Lorraine (UL), Agence de la biomédecine [Saint-Denis la Plaine], Institut de médecine moléculaire de Rangueil (I2MR), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-IFR150-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Fédérale Toulouse Midi-Pyrénées, Arbor Research Collaborative for Health, Service Néphrologie/Dialyse [AP-HP Ambroise-Paré], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Ambroise Paré [AP-HP], CKD REIN, and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)

Subjects
Adult, Male, medicine.medical_specialty, Adolescent, 030232 urology & nephrology, Renal function, 030204 cardiovascular system & hematology, Coronary artery disease, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Risk Factors, Internal medicine, Prevalence, medicine, Humans, Prospective Studies, cardiovascular diseases, Renal Insufficiency, Chronic, Aged, Aged, 80 and over, Transplantation, business.industry, valvular heart disease, Age Factors, Odds ratio, Middle Aged, medicine.disease, Plaque, Atherosclerotic, 3. Good health, Cardiovascular Diseases, Nephrology, Heart failure, Cohort, Albuminuria, Cardiology, Female, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, France, medicine.symptom, business, Glomerular Filtration Rate, Kidney disease
Abstract

Background Although chronic kidney disease (CKD) and age are major risk factors for cardiovascular disease (CVD), little is known about the relative proportions of atheromatous and non-atheromatous CVD by age in CKD patients. Methods We used baseline data from the French Chronic Kidney Disease-Renal Epidemiology and Information Network (CKD-REIN) cohort of 3033 patients (65% men) with CKD Stages 3–4 to study crude and adjusted associations between age, the estimated glomerular filtration rate (eGFR), atheromatous CVD (coronary artery disease, peripheral artery disease and stroke) and non-atheromatous CVD (heart failure, cardiac arrhythmia and valvular heart disease). Results Mean age was 66.8 and mean Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) eGFR was 32.9 mL/min/1.73 m2. In the Conclusions In this large cohort of CKD patients, both atheromatous and non-atheromatous CVD were highly prevalent and more frequent in older patients. In a given age group, the prevalence of atheromatous and non-atheromatous CVD was similar (except for a greater prevalence of non-atheromatous CVD after 85).

Published
2018

41. Comparaison de la survie technique de la dialyse péritonéale après réduction néphronique par néphrectomie en comparaison à l’embolisation artérielle rénale chez les patients polykystiques

Author

Pierre, M., primary, Kanagaratnam, L., additional, Moreau, K., additional, Sigogne, M., additional, Petrache, A., additional, Braconnier, A., additional, Petitpierre, F., additional, Lessore, C., additional, Lobbedez, T., additional, and Toure, F., additional

Published
2019
Full Text
View/download PDF

44. Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease

Author

Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang J, Czerwiec FS, Tempo team, Gross P, Schulze B, Bichet D, Chauveau D, Peeters P, Voiculescu M, Manunta P, Tuazon J, Watnick T, Goral S, Horie S, Nutahara K, Torres V, Chapman A, Gansevoort R, Perrone R, Czerwiec F, Goldstein S, Cowley B, Fukagawa M, Torra R, Wei LJ, Cook T, Toto R, Agarwal R, August P, Bakris G, Beddhu S, Corwin H, Ruilope L, Rosa-Diez G, De La Fuente J, Martin R, Massari P, Novoa P, Rial M, Wasserman A, Faull R, Fraser I, Johnson D, Pedagagos E, Lian M, Pollock C, Cooper B, Rangan G, Russ G, McDonald S, Thomas M, Khoo D, Walker R, Pirson Y, Laecke V, Van der Niepen P, Sennesael J, Barre P, Alam A, Soroka S, Dieperink H, Strandgaard S, Petersen L, Berthoux F, Canaud B, Gontiers-Picard A, Huart A, Combe C, Delmas Y, Dussol B, Laville M, Guebre-Egziabher F, Mignon F, Michel C, Rieu P, Noel N, Ryckelynck J, Lobbedez T, Dellanna F, Kleophas W, Feldkamp T, Witzke O, Nurnberger J, Zeltner R, Walz G, Zeier M, Sommerer C, Bianchi S, Capasso G, Miranda N, Magistroni R, Bracale M, Remuzzi G, Rota S, Villa G, Tilocca P, Asahi K, Kato T, Endo M, Umezono T, Fujigaki Y, Kato A, Fukatsu A, Hasegawa H, Tayama Y, Hasegawa M, Hosoya T, Hanaoka K, Iehara N, Iino Y, Tsuruoka S, Imai E, Isaka Y, Ishimura E, Ito S, Sato H, Kamata K, Sakamoto H, Kamura K, Kusano E, Muto S, Kuwahara M, Matsubara A, Yorioka N, Mochizuki T, Narita I, Naya Y, Nihei N, Yukio N, Nishio S, Nitta K, Tsuchiya K, Okamura M, Sasaki S, Rai T, Seta K, Sugawara A, Shibazaki S, Sugiyama S, Tabei K, Takaichi K, Tomita K, Kitamura K, Tsukamoto Y, Tsuruya K, Nakano T, Ubara Y, Watanabe T, Yamamoto T, Yoshida K, Ishii D, Yuzawa Y, Meijer E, Vervloet M, Ciechanowski K, Wisniewska M, Gutowska-Jablonska M, Marcinkowska-Królewicz M, Klatko W, Wiśniewski T, Klinger M, Krajewska M, Ksiazek A, Orłowska G, Malecki R, Gontarek-Kacprzak J, Nowicki M, Makówka A, Rutkowski B, Wołyniec W, Rydzewski A, Sulowicz W, Jasik P, Covic A, Volovat C, Mircescu G, Petrescu L, Bobeica R, Barbarash O, Chesnokova L, Borovoy S, Demina L, Shostka G, Idovu M, Tkalich L, Geynits O, Tomilina N, Foggensteiner L, Holt S, Kingswood J, Lambie S, Peel R, MacDougall I, Tucker B, MacPhee I, Maxwell A, Brown H, Mikhail A, Bastin L, Turner N, Neary J, Wheeler D, Maxwell P, Wilkie M, Ong A, Zehnder D, Aldridge N, Adler S, Klein M, Battle D, Bennett W, Berger B, Dell K, Blumenfeld J, Donahue S, Bolin P, Browder R, Perry A, Oskoui F, Culpepper M, Dahl N, Edelstein C, Clegg L, Fischer D, Kaplan M, Kaveh K, Pankhaniya R, Koren M, Mansur K, Lafayette R, Lamar W, Lee J, Mahnensmith R, Nachman P, Mottl A, Miskulin D, Petersen J, Radhakrishnan J, Roppolo M, Basireddy M, Rosner M, Bolton W, Schulman G, Steed L, Steinman T, Hogan M, Venuto R, Turban S, Winklhofer F., Cardiovascular Centre (CVC), Groningen Kidney Center (GKC), Torres, Ve, Chapman, Ab, Devuyst, O, Gansevoort, Rt, Grantham, Jj, Higashihara, E, Perrone, Rd, Krasa, Hb, Ouyang, J, Czerwiec, F, Tempo, Team, Gross, P, Schulze, B, Bichet, D, Chauveau, D, Peeters, P, Voiculescu, M, Manunta, P, Tuazon, J, Watnick, T, Goral, S, Horie, S, Nutahara, K, Torres, V, Chapman, A, Gansevoort, R, Perrone, R, Goldstein, S, Cowley, B, Fukagawa, M, Torra, R, Wei, Lj, Cook, T, Toto, R, Agarwal, R, August, P, Bakris, G, Beddhu, S, Corwin, H, Ruilope, L, Rosa-Diez, G, De La Fuente, J, Martin, R, Massari, P, Novoa, P, Rial, M, Wasserman, A, Faull, R, Fraser, I, Johnson, D, Pedagagos, E, Lian, M, Pollock, C, Cooper, B, Rangan, G, Russ, G, Mcdonald, S, Thomas, M, Khoo, D, Walker, R, Pirson, Y, Laecke, V, Van der Niepen, P, Sennesael, J, Barre, P, Alam, A, Soroka, S, Dieperink, H, Strandgaard, S, Petersen, L, Berthoux, F, Canaud, B, Gontiers-Picard, A, Huart, A, Combe, C, Delmas, Y, Dussol, B, Laville, M, Guebre-Egziabher, F, Mignon, F, Michel, C, Rieu, P, Noel, N, Ryckelynck, J, Lobbedez, T, Dellanna, F, Kleophas, W, Feldkamp, T, Witzke, O, Nurnberger, J, Zeltner, R, Walz, G, Zeier, M, Sommerer, C, Bianchi, S, Capasso, G, Miranda, N, Magistroni, R, Bracale, M, Remuzzi, G, Rota, S, Villa, G, Tilocca, P, Asahi, K, Kato, T, Endo, M, Umezono, T, Fujigaki, Y, Kato, A, Fukatsu, A, Hasegawa, H, Tayama, Y, Hasegawa, M, Hosoya, T, Hanaoka, K, Iehara, N, Iino, Y, Tsuruoka, S, Imai, E, Isaka, Y, Ishimura, E, Ito, S, Sato, H, Kamata, K, Sakamoto, H, Kamura, K, Kusano, E, Muto, S, Kuwahara, M, Matsubara, A, Yorioka, N, Mochizuki, T, Narita, I, Naya, Y, Nihei, N, Yukio, N, Nishio, S, Nitta, K, Tsuchiya, K, Okamura, M, Sasaki, S, Rai, T, Seta, K, Sugawara, A, Shibazaki, S, Sugiyama, S, Tabei, K, Takaichi, K, Tomita, K, Kitamura, K, Tsukamoto, Y, Tsuruya, K, Nakano, T, Ubara, Y, Watanabe, T, Yamamoto, T, Yoshida, K, Ishii, D, Yuzawa, Y, Meijer, E, Vervloet, M, Ciechanowski, K, Wisniewska, M, Gutowska-Jablonska, M, Marcinkowska-Królewicz, M, Klatko, W, Wiśniewski, T, Klinger, M, Krajewska, M, Ksiazek, A, Orłowska, G, Malecki, R, Gontarek-Kacprzak, J, Nowicki, M, Makówka, A, Rutkowski, B, Wołyniec, W, Rydzewski, A, Sulowicz, W, Jasik, P, Covic, A, Volovat, C, Mircescu, G, Petrescu, L, Bobeica, R, Barbarash, O, Chesnokova, L, Borovoy, S, Demina, L, Shostka, G, Idovu, M, Tkalich, L, Geynits, O, Tomilina, N, Foggensteiner, L, Holt, S, Kingswood, J, Lambie, S, Peel, R, Macdougall, I, Tucker, B, Macphee, I, Maxwell, A, Brown, H, Mikhail, A, Bastin, L, Turner, N, Neary, J, Wheeler, D, Maxwell, P, Wilkie, M, Ong, A, Zehnder, D, Aldridge, N, Adler, S, Klein, M, Battle, D, Bennett, W, Berger, B, Dell, K, Blumenfeld, J, Donahue, S, Bolin, P, Browder, R, Perry, A, Oskoui, F, Culpepper, M, Dahl, N, Edelstein, C, Clegg, L, Fischer, D, Kaplan, M, Kaveh, K, Pankhaniya, R, Koren, M, Mansur, K, Lafayette, R, Lamar, W, Lee, J, Mahnensmith, R, Nachman, P, Mottl, A, Miskulin, D, Petersen, J, Radhakrishnan, J, Roppolo, M, Basireddy, M, Rosner, M, Bolton, W, Schulman, G, Steed, L, Steinman, T, Hogan, M, Venuto, R, Turban, S, Winklhofer, F., University of Zurich, Torres, Vicente E, Feldkamp, Thorsten (Beitragende*r), and Witzke, Oliver (Beitragende*r)

Subjects
Male, Tolvaptan, Medizin, 2700 General Medicine, SIROLIMUS, Kidney, V2 RECEPTOR ANTAGONIST, 10052 Institute of Physiology, Aquaretic, VASOPRESSIN V-2-RECEPTOR ANTAGONIST, Polycystic Kidney, 10035 Clinic for Nephrology, Medicine (all), General Medicine, Organ Size, Middle Aged, Adolescent, Adult, Benzazepines, Double-Blind Method, Female, Glomerular Filtration Rate, Humans, Polycystic Kidney, Autosomal Dominant, Sodium, Young Adult, Antidiuretic Hormone Receptor Antagonists, LONG-ACTING SOMATOSTATIN, Autosomal Dominant, 10076 Center for Integrative Human Physiology, OPC-41061, medicine.symptom, medicine.drug, medicine.medical_specialty, RENAL-FUNCTION, CYST GROWTH, Autosomal dominant polycystic kidney disease, Urology, Renal function, Kidney Volume, 610 Medicine & health, Placebo, Article, VOLUME PROGRESSION, Cystic kidney disease, Internal medicine, medicine, HYPONATREMIA, business.industry, urogenital system, ORAL TOLVAPTAN, medicine.disease, Endocrinology, Albuminuria, 570 Life sciences, biology, business
Abstract

BACKGROUND: The course of autosomal dominant polycystic kidney disease (ADPKD) is often associated with pain, hypertension, and kidney failure. Preclinical studies indicated that vasopressin V 2 -receptor antagonists inhibit cyst growth and slow the decline of kidney function. METHODS: In this phase 3, multicenter, double-blind, placebo-controlled, 3-year trial, we randomly assigned 1445 patients, 18 to 50 years of age, who had ADPKD with a total kidney volume of 750 ml or more and an estimated creatinine clearance of 60 ml per minute or more, in a 2:1 ratio to receive tolvaptan, a V 2 -receptor antagonist, at the highest of three twice-daily dose regimens that the patient found tolerable, or placebo. The primary outcome was the annual rate of change in the total kidney volume. Sequential secondary end points included a composite of time to clinical progression (defined as worsening kidney function, kidney pain, hypertension, and albuminuria) and rate of kidney-function decline. RESULTS: Over a 3-year period, the increase in total kidney volume in the tolvaptan group was 2.8% per year (95% confidence interval [CI], 2.5 to 3.1), versus 5.5% per year in the placebo group (95% CI, 5.1 to 6.0; P

Published
2012

45. [Socioeconomic inequalities and kidney transplantation]

Author

Châtelet, V., Lobbedez, T., Harambat, J., Bayat-Makoei, S., Glowacki, F., Vigneau, C., CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), CHU Bordeaux [Bordeaux], Recherche en Pharmaco-épidémiologie et Recours aux Soins (REPERES), Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP), École des Hautes Études en Santé Publique [EHESP] (EHESP), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), CHU Pontchaillou [Rennes], Université de Rennes 1 (UR1), and Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-École des Hautes Études en Santé Publique [EHESP] (EHESP)

Subjects
Male, Greffe, Waiting Lists, Précarité, Kidney Transplantation, Health Services Accessibility, Socioeconomic Factors, Social insecurity, [SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology, Transplantation rénale, Humans, Socioeconomic inequalities, Rein, Inégalités sociales de santé, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Female, France, Poverty
Abstract

National audience; Studies at the population level must take into account the effect of social insecurity and socioeconomic inequalities on the patient outcomes. Socioeconomic inequalities depend on many determinants that are socially determined. In renal transplantation, these social determinants are not registered in the databases. The European Deprivation Index (EDI) is a composite index of social vulnerability with a French version. The EDI is an ecological measure of deprivation including the individual perception of basic needs for daily life that is called "subjective poverty". The Townsend index, Carstairs index and the Index of Multiple Deprivation are other ecological index available. It has been demonstrated in the United States that socioeconomic indicators of deprivation were associated with both the access to the waiting list for renal transplantation and transplantation failure. In France, socioeconomic deprivation may also affect the access to the waiting list and outcome of transplantation. This article is a review about deprivation and renal transplantation.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results